These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33221201)

  • 1. Impact of the Delayed Initiation of Adjuvant Chemotherapy in the Outcome of Triple Negative Breast Cancer.
    Morante Z; Ruiz R; Araujo JM; Pinto JA; Cruz-Ku G; Urrunaga-Pastor D; Namuche F; Flores C; Mantilla R; Luján MG; Fuentes H; Schwarz L; Aguilar A; Neciosup S; Gómez HL
    Clin Breast Cancer; 2021 Jun; 21(3):239-246.e4. PubMed ID: 33221201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer.
    Gagliato Dde M; Gonzalez-Angulo AM; Lei X; Theriault RL; Giordano SH; Valero V; Hortobagyi GN; Chavez-Macgregor M
    J Clin Oncol; 2014 Mar; 32(8):735-44. PubMed ID: 24470007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subpopulation treatment effect pattern plot analysis: a prognostic model for distant recurrence-free survival to estimate delayed adjuvant chemotherapy initiation effect in triple-negative breast cancer.
    Morante Z; Ferreyra Y; Pinto JA; Valdivieso N; Castañeda C; Vidaurre T; Valencia G; Rioja P; Fuentes H; Cotrina JM; Neciosup S; Gomez HL
    Front Oncol; 2023; 13():1193927. PubMed ID: 38023174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between initiation of adjuvant chemotherapy beyond 30 days after surgery and overall survival among patients with triple-negative breast cancer.
    Heeg E; Marang-van de Mheen PJ; Van Maaren MC; Schreuder K; Tollenaar RAEM; Siesling S; Bos MEMM; Vrancken Peeters MTFD
    Int J Cancer; 2020 Jul; 147(1):152-159. PubMed ID: 31721193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does time to adjuvant chemotherapy (TTC) affect outcomes in patients with triple-negative breast cancer?
    Pomponio MK; Keele LJ; Fox KR; Clark AS; Matro JM; Shulman LN; Tchou JC
    Breast Cancer Res Treat; 2019 Aug; 177(1):137-143. PubMed ID: 31119565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer.
    Chavez-MacGregor M; Clarke CA; Lichtensztajn DY; Giordano SH
    JAMA Oncol; 2016 Mar; 2(3):322-9. PubMed ID: 26659132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed initiation of adjuvant chemotherapy in older women with breast cancer.
    Smith-Graziani D; Lei X; Giordano SH; Zhao H; Karuturi M; Chavez-MacGregor M
    Cancer Med; 2020 Oct; 9(19):6961-6971. PubMed ID: 32767723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis.
    Gu Y; Wu G; Zou X; Huang P; Yi L
    Med Sci Monit; 2020 Feb; 26():e920432. PubMed ID: 32043484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged Time to Adjuvant Chemotherapy Initiation Was Associated with Worse Disease Outcome in Triple Negative Breast Cancer Patients.
    Cai L; Tong Y; Zhu X; Shen K; Zhu J; Chen X
    Sci Rep; 2020 Apr; 10(1):7029. PubMed ID: 32341397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
    de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
    Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
    Leon-Ferre RA; Jonas SF; Salgado R; Loi S; de Jong V; Carter JM; Nielsen TO; Leung S; Riaz N; Chia S; Jules-Clément G; Curigliano G; Criscitiello C; Cockenpot V; Lambertini M; Suman VJ; Linderholm B; Martens JWM; van Deurzen CHM; Timmermans AM; Shimoi T; Yazaki S; Yoshida M; Kim SB; Lee HJ; Dieci MV; Bataillon G; Vincent-Salomon A; André F; Kok M; Linn SC; Goetz MP; Michiels S;
    JAMA; 2024 Apr; 331(13):1135-1144. PubMed ID: 38563834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database.
    Du ZL; Wang Y; Wang DY; Zhang L; Bian ZM; Deng Y; Xu CS; Lin DC; Xie L; Jia Y; Gao JD; Zhang BL
    Breast Cancer Res Treat; 2020 Sep; 183(2):429-438. PubMed ID: 32647940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with early triple negative breast cancer.
    Hatzipanagiotou ME; Pigerl M; Gerken M; Räpple S; Zeltner V; Hetterich M; Ugocsai P; Inwald EC; Klinkhammer-Schalke M; Ortmann O; Seitz S
    Breast Cancer Res Treat; 2024 Apr; 204(3):607-615. PubMed ID: 38238552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival according to the site of metastasis in triple-negative breast cancer patients: The Peruvian experience.
    Piedra-Delgado L; Chambergo-Michilot D; Morante Z; Fairen C; Jerves-Coello F; Luque-Benavides R; Casas F; Bustamante E; Razuri-Bustamante C; Torres-Roman JS; Fuentes H; Gomez H; Narvaez-Rojas A; De la Cruz-Ku G; Araujo J
    PLoS One; 2024; 19(2):e0293833. PubMed ID: 38300959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
    Ren YX; Hao S; Jin X; Ye FG; Gong Y; Jiang YZ; Shao ZM
    Breast; 2019 Feb; 43():97-104. PubMed ID: 30529406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer.
    Farolfi A; Scarpi E; Rocca A; Mangia A; Biglia N; Gianni L; Tienghi A; Valerio MR; Gasparini G; Amaducci L; Faedi M; Baldini E; Rubagotti A; Maltoni R; Paradiso A; Amadori D
    Eur J Cancer; 2015 Sep; 51(14):1874-81. PubMed ID: 26206258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
    Leon-Ferre RA; Polley MY; Liu H; Gilbert JA; Cafourek V; Hillman DW; Elkhanany A; Akinhanmi M; Lilyquist J; Thomas A; Negron V; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Visscher DW; Goetz MP
    Breast Cancer Res Treat; 2018 Jan; 167(1):89-99. PubMed ID: 28913760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer.
    Zhai Z; Zheng Y; Yao J; Liu Y; Ruan J; Deng Y; Zhou L; Zhao P; Yang S; Hu J; We B; Wu Y; Zhang D; Kang H; Dai Z
    JAMA Netw Open; 2020 Nov; 3(11):e2021881. PubMed ID: 33211105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer.
    Pan K; Guan XX; Li YQ; Zhao JJ; Li JJ; Qiu HJ; Weng DS; Wang QJ; Liu Q; Huang LX; He J; Chen SP; Ke ML; Zeng YX; Xia JC
    Clin Cancer Res; 2014 Jun; 20(11):3003-11. PubMed ID: 24668644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active behavior of triple-negative breast cancer with adipose tissue invasion: a single center and retrospective review.
    Yamaguchi J; Moriuchi H; Ueda T; Kawashita Y; Hazeyama T; Tateishi M; Aoki S; Uchihashi K; Nakamura M
    BMC Cancer; 2021 Apr; 21(1):434. PubMed ID: 33879104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.